Phase III RCC 1L Combo
Research payments
$2,330,129
Through program year 2021, $2,330,129 in research payments was reported against Phase III RCC 1L Combo, across 100 payments.
- Paid by (largest first)
- E.R. Squibb & Sons, L.L.C.; Celgene Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $415,990 | 27 |
| 2020 | Research | $1,465,210 | 39 |
| 2019 | Research | $448,930 | 34 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Asim Amin Charlotte, NC Named on 5 payments
- David McDermott Boston, MA Named on 4 payments
- Sumanta Pal Duarte, CA Named on 4 payments
- Theodore Logan Indianapolis, IN Named on 4 payments
- Elisabeth Heath Detroit, MI Named on 3 payments
- Nizar Tannir Houston, TX Named on 3 payments
- Thomas Hutson Dallas, TX Named on 3 payments
- Robert Motzer New York, NY Named on 3 payments
- Saby George Buffalo, NY Named on 2 payments
- Philippe Spiess Tampa, FL Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.